格列衛(wèi)對慢性粒細(xì)胞白血病Ph染色體和bcr-abl基因表達的影響.pdf

1、青島大學(xué)碩士學(xué)位論文格列衛(wèi)對慢性粒細(xì)胞白血病Ph染色體和bcrabl基因表達的影響姓名：李萍申請學(xué)位級別：碩士專業(yè)：臨床檢驗診斷學(xué)指導(dǎo)教師：吳春梅管洪在20090602TheEffectofImatinibMesylateTherapyonPhchromosomeandbcrlablGeneExpressioninPatientswithCMLAbstractObjective：TodetcetthechangesofPhiladelp

2、hia(Ph)chromosomeandbcr／ablfusiongeneexpressionbeforeandafterimatinibmesylate(STl571，Gleevec)therapyinPhchromosomepositiveChronicMyeloidleukemia(CML)ArelatedgoalWaStoevaluatetheprognosisandtherapeuticeffectinthosepatient

3、streatedwithimatinibmesylateMethods：Atotalof11PhchromosomepositiveCMLpatientswereenrolleelintoourstudyChromosomespecimenspreparationofbonemallowcellsweremadeusingdirectandshorttermcultureTotalRNAWiltsextractedbytheTrizol

4、ReagentmethodandquantifiedspectrophotometricallyThekaryotypeandbcr／ablfusiongenesexpressionbeforeandafterimatinibmesylatetherapywereanalyzedbyRbandingandsemi—quantitativereversetranscriptasepolymerasechainreaction(RT—PCR

5、)，respectivelyResults：Amongthe11patients，7easesforwhomtreated州n1imatinibmesylatefor3months，achievedacompletecytogeneticremmision(CCyR)withomanyPhchromosomepositivecellsOnecaseinchromephasetreatedfor2months，whosePhchromos

6、omepositiveratewas30％，achievedmajorcytogeneticremmision(MCyR)Onecaseinblastcrisisphasetreatedfor6months，itsPhchromosomepositiveratereducedto70％Onecaseinacceleratedphasetreatedfor12months，itsPhchromosomepositiverateWas60％

7、Anothercaseinchromephasetreatedfor1monththechromosomepositiverateWasstill100％Bcr／ablfusiongeneexpressionsaftertreatedwithimatinibmesylateweredecreasedobviouslycomparedwiththatpretreatmentina11cases(t=3774，513；p001)Conclu